DR. ROOZBEH MOHAJER MD NPI 1457538449

NPI Details

DR. Roozbeh Mohajer, MD is a hematology and oncology internal medicine in Palo Alto, CA with 22 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Roozbeh Mohajer, MD NPI is 1457538449. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

The provider's business location address is:

795 EL CAMINO REAL FL 2
PALO ALTO, CA
ZIP 94301
Phone: (650) 853-2905
Fax: (650) 853-2966

The NPI 1457538449 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1459)
• Bcg live intravesical instillation, 1 mg (HCPCS:J9030)
• Injection, infliximab, excludes biosimilar, 10 mg (HCPCS:J1745)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Injection, pegfilgrastim-cbqv, biosimilar, (udenyca), 0.5 mg (HCPCS:Q5111)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional (HCPCS:99211)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Injection of drug or substance into vein (HCPCS:96374)
• Instillation of anti-cancer drug into bladder (HCPCS:51720)
• Drawing of blood for a medical problem (HCPCS:99195)

The enumeration date for this NPI number is 1/22/2008 and was last updated on 6/3/2020.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: